Shengping HOU | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Prof. Shengping HOU | Medicine and Dentistry | Best Researcher Award

Director of Beijing Institute of Ophthalmology at Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, China

Dr. Shengping Hou is a prominent figure in ophthalmology, currently serving as a Professor and Director at the Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University. With extensive experience in ocular immunology and stem cell biology, he has contributed significantly to advancing research in vision science. His leadership roles and numerous research grants highlight his dedication to developing innovative solutions for ocular diseases. Dr. Hou has delivered invited lectures at international conferences and is actively engaged in professional service, serving as an ad hoc reviewer for esteemed journals. His work has earned him several prestigious awards, including national recognition for his achievements in science and technology.

Professional Profile

Education

Dr. Hou earned his Ph.D. in Ocular Immunology from Sun Yat-sen University, China, in 2009, showcasing his foundation in understanding immune-related ocular diseases. He further honed his expertise as a postdoctoral fellow in Ocular Stem Cell Biology at the University of California, San Francisco, in 2016. This educational background has equipped him with cutting-edge knowledge and skills, enabling him to explore and address complex issues in ophthalmology.

Professional Experience

Dr. Hou began his career as an Associate Professor at Chongqing Medical University (2009–2015), where he played a key role in ophthalmology research at the Chongqing Key Laboratory of Ophthalmology. In 2015, he was promoted to Professor, continuing his impactful work at the same institution until 2023. Currently, Dr. Hou serves as the Director at the Beijing Institute of Ophthalmology, where he leads advanced research initiatives and oversees clinical operations.

Research Interests

Dr. Hou’s research interests focus on ocular immunology, ocular stem cell biology, and the genetic basis of ocular diseases. His work delves into understanding the molecular and genetic mechanisms underlying conditions such as VKH syndrome and Behçet’s disease, with the aim of developing innovative treatments. His commitment to translating basic research into clinical solutions highlights his dedication to improving patient outcomes in ophthalmology.

Research Skills

Dr. Hou possesses advanced expertise in genetic and molecular studies, including gene editing and analysis of copy number variants. His skills also encompass stem cell culture techniques, immunological assays, and bioinformatics tools for studying ocular diseases. Additionally, his experience in securing and leading research grants demonstrates his strategic planning and leadership abilities in scientific endeavors.

Awards and Honors

Dr. Hou has received numerous awards for his contributions to ophthalmology and scientific research. These include the First Prize for the Achievement in Science and Technology from Chongqing (2010, 2015) and the Chinese Health Ministry (2012). In 2018, he was awarded the Second Prize for Scientific and Technological Progress of China, reflecting the national recognition of his impactful work. His accolades underscore his commitment to advancing knowledge in vision science and his leadership in the field.

Conclusion

Dr. Shengping Hou is a highly accomplished researcher with significant contributions to ocular immunology and stem cell biology. His academic leadership, research funding success, and national awards make him a strong candidate for the Best Researcher Award. However, further emphasis on international collaboration, impactful publications, and translational innovations could make his candidature even more competitive. Overall, Dr. Hou’s accomplishments and leadership in ophthalmology research align well with the criteria for this prestigious award.

Publication Top Notes

  1. Ocular immune-related diseases: molecular mechanisms and therapy”
    • Authors: Wang, Y.; Gao, S.; Cao, F.; Lei, F.; Hou, S.
    • Year: 2024
  2. “m6A-methylase METTL3 promotes retinal angiogenesis through modulation of metabolic reprogramming in RPE cells”
    • Authors: Zhou, Q.; Liu, X.; Lu, H.; Yang, P.; Hou, S.
    • Year: 2024
  3. “A novel metric of autoimmune disease burden and its estimated incidence across different stages in the life cycle of women”
    • Authors: Cao, F.; Pan, H.-F.; Hou, S.
    • Year: 2024
  4. “A feedback loop driven by H3K9 lactylation and HDAC2 in endothelial cells regulates VEGF-induced angiogenesis”
    • Authors: Fan, W.; Zeng, S.; Wang, X.; Li, N.; Hou, S.
    • Year: 2024
    • Citations: 3
  5. “Transcription factor EGR2 alleviates autoimmune uveitis via activation of GDF15 to modulate the retinal microglial phenotype”
    • Authors: Li, W.; He, S.; Tan, J.; Yang, P.; Hou, S.
    • Year: 2024
    • Citations: 2
  6. “Icariin alleviates oxygen-induced retinopathy by targeting microglia hexokinase 2”
    • Authors: Li, X.; Wang, G.; Li, N.; Zhou, Q.; Hou, S.
    • Year: 2024
    • Citations: 1
  7. “Autophagy-mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization”
    • Authors: Liu, X.; Zhou, Q.; Meng, J.; Mao, L.; Hou, S.
    • Year: 2024
    • Citations: 1
  8. “Polyvinylpyrrolidone-curcumin nanoparticles with immune regulatory and metabolism regulatory effects for the treatment of experimental autoimmune uveitis”
    • Authors: Cao, F.; Liang, K.; Tang, W.-W.; Tao, L.-M.; Wang, X.
    • Year: 2024
    • Citations: 6
  9. “Trends and cross-country inequalities in the global burden of osteoarthritis, 1990–2019: A population-based study”
    • Authors: Cao, F.; Xu, Z.; Li, X.-X.; Hou, S.; Pan, H.-F.
    • Year: 2024
    • Citations: 14
  10. “YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes”
    • Authors: Huang, J.; Wang, X.; Li, N.; Yang, P.; Hou, S.
    • Year: 2024
    • Citations: 9

 

Dimitrios Moris | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. Dimitrios Moris | Medicine and Dentistry | Best Researcher Award

MD, MSc, PhD at Georgetown University, United States

Dr. Dimitrios Paraskevas Moris is an accomplished surgeon and researcher with a focus on abdominal multi-organ transplantation and hepatopancreatobiliary (HPB) surgery. He is currently completing a fellowship at MedStar Georgetown University, Washington DC, in abdominal and multivisceral transplantation. With a robust academic background, Dr. Moris has worked in multiple prestigious institutions, including Duke University and Ohio State University, where he specialized in various research fellowships. His professional interests encompass liver transplantation, pancreatic surgery, and aortic aneurysm research. In addition to his clinical training, Dr. Moris has received several scholarships and awards, affirming his excellence in both research and practice. His career trajectory demonstrates a deep commitment to advancing medical knowledge, particularly in the fields of transplantation and surgery, where he applies his diverse expertise to patient care and scientific advancement.

Professional Profile

Education:

Dr. Moris holds an extensive educational background that spans multiple degrees and prestigious institutions. He completed his M.D. at the National and Kapodistrian University of Athens in 2010, graduating with distinction. He later pursued a Ph.D. in the same university, focusing on the role of serum calprotectin in abdominal aortic aneurysm development, for which he earned unanimous excellent recognition. Dr. Moris also holds an MSc in Endovascular Techniques from the National and Kapodistrian University of Athens, complementing his extensive academic training. Throughout his career, he has further advanced his expertise through fellowships at renowned institutions like Ohio State University, Duke University, and MedStar Georgetown University, where he currently holds a fellowship in abdominal transplantation and HPB surgery.

Professional Experience:

Dr. Moris’ professional experience is marked by his diverse roles in academia and clinical practice. He currently serves as a fellow in abdominal and multivisceral transplantation and hepatopancreatobiliary surgery at MedStar Georgetown University Hospital. Prior to this, he completed a general surgery residency at Duke University Medical Center, where he also worked as a research fellow. His experience includes significant time spent as a research fellow at Ohio State University and Cleveland Clinic Foundation, contributing to cutting-edge research in liver transplantation and cancer treatment. His clinical experience spans multiple prestigious institutions, where he trained and practiced in general surgery, transplantation, and vascular surgery, including the Laikon General Hospital in Athens, Greece.

Research Interests:

Dr. Moris’ research interests are concentrated on the intersection of transplantation, surgical oncology, and vascular surgery. He has explored aortic aneurysm repair, particularly focusing on the comparison between open and endovascular techniques. His Ph.D. research on serum calprotectin’s role in abdominal aortic aneurysm development exemplifies his dedication to understanding complex mechanisms in surgical pathology. Additionally, Dr. Moris has contributed extensively to the fields of liver transplantation and hepatopancreatobiliary surgery, researching novel therapeutic approaches and techniques to improve patient outcomes. His interests also extend to cancer research, especially the management of hepatocellular carcinoma and related oncological conditions.

Research Skills:

Dr. Moris possesses advanced research skills honed through extensive experience in high-level academic settings. He is proficient in experimental design, data analysis, and scientific writing, with numerous publications in top-tier medical journals. His research methodology includes both clinical and laboratory-based approaches, with particular expertise in translational research related to transplantation and surgical oncology. Dr. Moris is skilled in using advanced statistical tools and is adept at conducting complex surgeries and post-operative care in research settings. His collaborative nature and extensive mentorship from renowned researchers have enabled him to contribute to significant scientific discoveries and advancements in the fields of surgery and transplantation.

Awards and Honors:

Dr. Moris has received numerous awards and honors throughout his career, reflecting his outstanding contributions to medicine and surgery. Notable accolades include the Dr. Robert W. Kieffer Best Research Paper Award, the ABSITE Examination Excellence Award, and the Surgical Autonomy Program Evaluation Award. In addition to his clinical achievements, Dr. Moris has been recognized for his research excellence with prestigious scholarships, including the Alexander S. Onassis Foundation Scholarship and the Thorax Foundation Scholarship for postdoctoral research. He is also a member of the Sigma Xi Scientific Research Honor Society and has received multiple leadership and teaching awards, further underscoring his multifaceted contributions to the medical field. These honors highlight his dedication to advancing surgical practice and medical research.

Conclusion:

Dimitrios Paraskevas Moris exemplifies the qualities of a top-tier researcher with substantial expertise, impactful publications, leadership recognition, and a global research presence. His consistent contribution to medical research, particularly in surgery and transplantation, paired with his dedication to advancing clinical practices, makes him a strong candidate for the Best Researcher Award. Further exploration of interdisciplinary research and collaboration could further solidify his place as a leading figure in his field.

Publication Top Notes

  • Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study
    • Authors: COVIDSurg Collaborative
    • Year: 2021
    • Citations: 425
    • Journal: Anaesthesia, 76(6), 748-758
  • From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world
    • Authors: D Dimitroulis, C Damaskos, S Valsami, S Davakis, N Garmpis, E Spartalis, …
    • Year: 2017
    • Citations: 364
    • Journal: World Journal of Gastroenterology, 23(29), 5282
  • Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study
    • Authors: CCGS Collaborative
    • Year: 2021
    • Citations: 298*
    • Journal: Anaesthesia
  • Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
    • Authors: J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, …
    • Year: 2021
    • Citations: 266
    • Journal: The Lancet Oncology, 22(11), 1507-1517
  • The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox
    • Authors: D Moris, M Spartalis, E Spartalis, GS Karachaliou, GI Karaolanis, …
    • Year: 2017
    • Citations: 263
    • Journal: Annals of Translational Medicine, 5(16)
  • Diagnosis and management of acute appendicitis in adults: a review
    • Authors: D Moris, EK Paulson, TN Pappas
    • Year: 2021
    • Citations: 261
    • Journal: JAMA, 326(22), 2299-2311
  • Amyand’s hernia: a review
    • Authors: A Michalinos, D Moris, S Vernadakis
    • Year: 2014
    • Citations: 258
    • Journal: The American Journal of Surgery, 207(6), 989-995
  • Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
    • Authors: D Moris, M Palta, C Kim, PJ Allen, MA Morse, ME Lidsky
    • Year: 2023
    • Citations: 212
    • Journal: CA: A Cancer Journal for Clinicians, 73(2), 198-222
  • Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer
    • Authors: C Damaskos, S Valsami, M Kontos, E Spartalis, T Kalampokas, …
    • Year: 2017
    • Citations: 208
    • Journal: Anticancer Research, 37(1), 35-46
  • Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review
    • Authors: DI Tsilimigras, I Ntanasis-Stathopoulos, F Bagante, D Moris, J Cloyd, …
    • Year: 2018
    • Citations: 178
    • Journal: Surgical Oncology, 27(2), 280-288

Ting-Ting Chang | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Ting-Ting Chang l Medicine and Dentistry l Best Researcher Award

Associate Professor at National Yang Ming Chiao Tung University, Taiwan

Dr. Ting-Ting Chang is an Associate Professor at National Yang Ming Chiao Tung University, specializing in vascular medicine, kidney disease, diabetes, and new drug development. With a Ph.D. from National Yang-Ming University, Dr. Chang has a robust publication record in high-impact journals, including Science Translational Medicine and Angiogenesis. Recognized with awards such as the Young Scientists Award and the Young Investigator Fellowship, Dr. Chang is also a full member of Sigma Xi and other prestigious societies. Their research is notable for its innovation and significant contributions to understanding and treating complex diseases.

Profile:

Education

Ting-Ting Chang, Ph.D., earned her Ph.D. in Pharmacology from National Yang-Ming University in Taipei, Taiwan, in 2015. Her educational journey is distinguished by her continued academic and research excellence, which laid a strong foundation for her current role as an Associate Professor in the Department and Institute of Pharmacology at National Yang Ming Chiao Tung University. Prior to this, Dr. Chang completed her post-doctoral research at the same institution, further solidifying her expertise in pharmacology and related fields.

Professional Experience

Ting-Ting Chang, Ph.D., is an accomplished researcher and academic with extensive experience in the field of pharmacology. Currently serving as an Associate Professor at the Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Dr. Chang has previously held roles as an Assistant Professor and Post-doctoral Researcher at the same institution. Their career spans significant contributions to vascular medicine, kidney disease, diabetes, and new drug development, with a track record of high-impact research and numerous publications in leading scientific journals.

Research Interest

Ting-Ting Chang’s research interests encompass a broad range of topics within vascular medicine and molecular biology, focusing on the mechanisms underlying vascular dysfunction, kidney disease, and diabetes mellitus. Her work includes experimental animal model design and new drug development, aiming to uncover novel therapeutic targets and strategies for these critical health issues. Dr. Chang’s research integrates molecular and cellular approaches to address complex pathological conditions, contributing significantly to advancements in understanding and treating vascular and metabolic disorders.

Research Skills

Ting-Ting Chang, Ph.D., demonstrates exceptional research skills through a robust portfolio of high-impact publications and significant contributions to fields such as vascular medicine, kidney disease, and diabetes. With a strong academic background and extensive experience as both an Associate Professor and Post-doctoral Researcher, Dr. Chang excels in designing and conducting innovative studies, particularly in identifying novel therapeutic targets and mechanisms. Their proficiency in experimental animal model design and new drug development further highlights their expertise, while their membership in prestigious scientific societies and receipt of notable awards underscore their recognition and influence in the research community.

Award and Recognition

Ting-Ting Chang, Ph.D., has garnered significant awards and recognition throughout their career, underscoring their outstanding contributions to research. Notably, Dr. Chang received the Young Scientists Award at the 55th Annual Scientific Meeting of the Japan Atherosclerosis Society in 2023 and the Young Investigator Fellowship Award at the 88th European Atherosclerosis Society Congress in 2020. In addition, Dr. Chang was awarded full membership of Sigma Xi in 2023, reflecting their esteemed position in the scientific community and their impactful research in vascular medicine, kidney disease, and diabetes.

Conclusion

Ting-Ting Chang, Ph.D., is a highly qualified candidate for the Best Researcher Award. Their exceptional contributions to vascular medicine, kidney disease, and diabetes, along with a strong publication record and recognition in the scientific community, underscore their suitability for this award. Addressing areas for improvement, such as expanding research applications and increasing public engagement, could further enhance their profile as a leading researcher. Overall, Dr. Chang’s dedication, innovative research, and professional achievements make them an excellent contender for the Best Researcher Award.

Publication Top Notes

  • Association between vitiligo and risk of retinal detachment: a population-based cohort study in Taiwan
    • Authors: Chen, C.-L., Wu, C.-Y., Chen, Y.-L., Chang, Y.-T., Wu, C.-Y.
    • Year: 2024
    • Citations: 0
  • Rejuvenation of the dorsal hand by injectable poly-D, L-lactic acid: A pilot study
    • Authors: Ma, S.-H., Lin, C.-Y., Lin, J.-Y., Chang, Y.-T., Chen, C.-C.
    • Year: 2024
    • Citations: 0
  • Correlation of Disease Severity, Proinflammatory Cytokines, and Reduced Brain Gray Matter Volumes in Patients with Atopic Dermatitis
    • Authors: Li, C.-Y., Chang, W.-C., Chen, M.-H., Chen, Y.-Y., Bai, Y.-M.
    • Year: 2024
    • Citations: 0
  • Risk of Type 1 Diabetes Mellitus in Patients with Atopic Dermatitis: A Nationwide Population-Based Cohort Study
    • Authors: Li, M.-C., Wu, C.-Y., Chang, Y.-T., Lyu, Y.-S., Wu, C.-Y.
    • Year: 2023
    • Citations: 0
  • Assoziation zwischen chronischer Nierenerkrankung und dem Risiko für bullöses Pemphigoid: eine nationale bevölkerungsbasierte Kohortenstudie
    • Authors: Yu, W.-T., Ma, S.-H., Wu, C.-Y., Chang, Y.-T., Wu, C.-Y.
    • Year: 2023
    • Citations: 1

Royston Liew | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Mr. Royston Liew | Medicine and Dentistry | Best Researcher Award

Student at Duke-NUS Medical School, Singapore

Dr. Liew Yew Meng Royston is an emerging researcher with a background in Chemical and Biomolecular Engineering, focusing on the molecular mechanisms underlying Hepatocellular Carcinoma (HCC), particularly in None-B-None-C HCC patients. His research integrates engineering principles with biological sciences, offering a novel approach to understanding complex disease pathways, such as bile acid homeostasis. Dr. Royston is proactive in his research endeavors, having initiated wet-lab experiments months in advance under the guidance of Professor Pierce Chow. His work has led to significant findings in the role of post-translational modifications in liver-gut homeostasis. In addition to his research, Dr. Royston has been recognized for his innovation with multiple patents and awards, including the National Runner-Up in the James Dyson Award for his work in vertical farming. His interdisciplinary approach and commitment to advancing medical research make him a promising figure in the field of oncology and biomedical engineering.

Profile

Education

Dr. Liew Yew Meng Royston holds a Bachelor of Engineering (Honours) in Chemical and Biomolecular Engineering from Nanyang Technological University, Singapore, where he studied from 2018 to 2022. His academic training provided a strong foundation in engineering principles, which he has effectively applied to his research in the biomedical field. During his undergraduate studies, Dr. Royston demonstrated a keen interest in integrating engineering with biological systems, laying the groundwork for his current research in Hepatocellular Carcinoma (HCC). His educational journey was marked by academic excellence, earning him a place on the Dean’s List for the 2018/2019 academic year. The interdisciplinary nature of his education has equipped Dr. Royston with the skills to approach complex biological problems with precision and innovation, making significant contributions to his field. His commitment to academic and research excellence continues to drive his pursuit of advanced knowledge in medicine and biomedical engineering.

Professional Experience

Dr. Liew Yew Meng Royston has demonstrated considerable professional experience in both research and innovation. He is currently focused on Hepatocellular Carcinoma (HCC) research, specifically None-B-None-C HCC (NBNC HCC), where he applies his background in chemical and biomolecular engineering to investigate bile acid homeostasis and its implications for liver function. Before beginning his Duke-NUS Phase 3 Scholarly Research Project, Dr. Royston proactively engaged in preliminary research with Professor Pierce Chow, resulting in significant novel findings. His research approach integrates engineering principles with biological systems, employing techniques such as molecular pathway modeling and process optimization. Beyond his research, Dr. Royston has made notable contributions to the field of vertical farming, with a patent for a modular hydroponic system and recognition through awards like the James Dyson Award and the APAC CEO of the Year Awards. His expertise reflects a blend of scientific rigor and innovative problem-solving.

Research Interest

Dr. Liew Yew Meng Royston’s research interest centers on elucidating the molecular and cellular mechanisms underlying Hepatocellular Carcinoma (HCC), specifically focusing on None-B-None-C Hepatocellular Carcinoma (NBNC HCC). His work involves investigating the dysregulation of bile acid homeostasis pathways and their impact on liver function in NBNC HCC patients. By applying principles from Chemical and Biomolecular Engineering, Dr. Royston integrates metabolomic, microbiomic, and transcriptomic data to identify critical alterations in disease mechanisms. His research explores the role of post-translational modifications, particularly acetylation of the FXR protein, in influencing bile acid production and liver-gut homeostasis. Additionally, he investigates the effects of highly processed diets on the microbiome and their subsequent role in HCC development. Dr. Royston’s interdisciplinary approach aims to deepen understanding of HCC and develop innovative strategies for its treatment, blending engineering precision with advanced biological research.

Research Skills

Dr. Liew Yew Meng Royston possesses a diverse skill set tailored to his research in Hepatocellular Carcinoma (HCC). His skills include advanced techniques in metabolomics, microbiomics, and transcriptomics, which are essential for analyzing complex biological data. Dr. Royston is proficient in molecular pathway modeling and process optimization, applying engineering principles to biological systems. His expertise extends to wet-lab experimentation, including the study of post-translational modifications of proteins and their effects on gene transcription. Additionally, Dr. Royston employs systems-level approaches to integrate various biological and biochemical data, enhancing the precision and depth of his research. His proactive approach to research, demonstrated by initiating preliminary work and securing foundational results, further highlights his commitment and technical capabilities in addressing complex biomedical challenges.

Award and Recognition

Dr. Liew Yew Meng Royston has received significant recognition for his contributions to research and innovation. Notably, he was awarded the National Runner-Up position in the James Dyson Award in 2022 for his work on vertical farming, highlighting his innovative approach to urban agriculture. His invention of a modular hydroponic farming apparatus was patented internationally, underscoring his inventive capabilities. In addition to these achievements, Dr. Royston received the APAC CEO of the Year Awards for Most Innovative Agribusiness CEO in 2022, reflecting his impact on the agribusiness sector. His research efforts have also been supported by several grants, including the SSG Tech POC Grant of $250,000 and the SSG Founder’s Startup Grant of $50,000. Dr. Royston’s academic excellence was recognized through his inclusion on the Dean’s List at Nanyang Technological University for the academic year 2018/2019, further attesting to his dedication and outstanding performance in his field.

Conclusion

Liew Yew Meng Royston demonstrates significant potential as a researcher with a strong interdisciplinary approach and innovative mindset. His proactive research efforts, combined with his engineering background, position him as a promising candidate for the Best Researcher Award. However, enhancing his publication record and securing research grants could further solidify his standing in the research community.

Publication Top Notes

Diagnostic laparoscopy for pre-operative selection of patients with known peritoneal carcinomatosis for CRS-HIPEC: A systematic review and meta-analysis

  • Authors: Ang, A.J.Y., Liew, R.Y.M., Aw, V.Z.J., Chia, C.S., Shannon, N.B.
  • Year: 2024
  • Journal: European Journal of Surgical Oncology
  • Volume: 50
  • Issue: 11
  • Article Number: 108623